Brian Chan Kai, MD
Retina Specialist · Portland, ORNPI 1578690566
Payments from drug & device makers
Across 316 payments — averaging $2647.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$241K
- Roche TCRC, Inc.$201K
- Genentech, Inc.$72K
- AstraZeneca$65K
- Regeneron Healthcare Solutions, Inc.$58K
- Ocular Therapeutix, Inc.$55K
- plus $145K from 17 others
What the payments were for
- Consulting fees$24,91616%
- Speaking & faculty fees$116,36375%
- Travel & lodging$6,9564%
- Food & beverage$6,7194%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 60 | $241,177 |
| Roche TCRC, Inc. | 15 | $200,706 |
| Genentech, Inc. | 31 | $71,515 |
| AstraZeneca | 4 | $65,072 |
| Regeneron Healthcare Solutions, Inc. | 35 | $57,822 |
| Ocular Therapeutix, Inc. | 5 | $55,381 |
| Regeneron | 26 | $44,039 |
| Astellas Pharma Global Development | 5 | $32,706 |
| AbbVie(2 entities) | 30 | $18,914 |
| Novartis | 11 | $15,120 |
| Genentech USA, Inc. | 25 | $11,044 |
| Boehringer Ingelheim | 2 | $10,650 |
| Baxter Healthcare | 24 | $5,100 |
| Harrow Eye, LLC | 4 | $3,523 |
| Boehringer Ingelheim International GmbH | 21 | $1,749 |
| Astellas Pharma US Inc | 8 | $720 |
| Alcon | 3 | $470 |
| Bausch & Lomb Americas Inc. | 2 | $309 |
| Alimera Sciences, Inc. | 1 | $154 |
| Cardinal Health 110 LLC | 1 | $150 |
| ANI Pharmaceuticals, Inc. | 1 | $119 |
| Sandoz | 1 | $79 |
| Topcon Healthcare, Inc. | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$836,573 in reported general payments places this provider in the 85th percentile of 36 retina specialist providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 104 | $5,867 |
| MoxifloxacinMoxifloxacin Hcl | 46 | $1,233 |
| Eplerenone | 15 | $1,043 |
| Ketorolac Tromethamine | 18 | $410 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $268 |
| Brimonidine Tartrate | 13 | $236 |
| Diclofenac Sodium | 20 | $194 |
| Latanoprost | 19 | $181 |
| Timolol Maleate | 16 | $120 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Portland
- Paul TlucekPortland$4.8M
- Apurva PatelPortland$1.1M
- David WilsonPortland$498K
- Michael LeePortland$479K
- Christina FlaxelPortland$358K
- John CampbellPortland$302K
- Brandon LujanPortland$147K
- Andreas LauerPortland$147K
- Steven BaileyPortland$141K
- Sirichai PasadhikaPortland$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.